Healthcare AI Vendor Renewal: A Scorecard for Value, Risk and Exit Readiness

Author: Eunoia Consulting Co. | Published: November 4, 2026

Before renewing a healthcare AI contract, review local value, total costs, human review workload, incidents, data permissions and exit readiness. Use this proposed scorecard to choose renewal, enforceable conditions, reduced scope or a planned exit.

Key Takeaways

  • Start the annual renewal review before the contractual notice deadline, using evidence relevant to the service and scope being renewed.
  • Assess local value against the next term's total operating commitment, including human review, correction and support costs.
  • Rate each domain as supported, conditional, unacceptable or unknown without allowing favourable pricing to cancel unresolved risks.
  • Review accumulated changes, incident remedies and current data-use permissions before committing to another contract term.
  • Check usable exports and continuity arrangements, then record a decision to renew, impose conditions, reduce scope or plan an exit.

Renew a healthcare AI contract only when current evidence supports its value, the organisation can sustain its human review obligations, and material risks and exit arrangements are understood. A lower price should not compensate for unresolved safety concerns, unclear data use or an untested route out of the service.

The scorecard below is a proposed operating framework for annual renewal decisions, not a legal requirement or certification scheme. It helps procurement, clinical and operational leaders decide whether to renew, negotiate conditions, restrict scope or exit. The question is not whether the vendor looked credible when selected. It is whether another contract term is justified now.

Start before the renewal notice deadline

Work backwards from the contractual notice deadline, not just the expiry date. Identify auto-renewal provisions, price changes, minimum commitments and the time needed to transition safely. Assign one renewal owner, with named contributors from the workflow team, finance, procurement, information security and privacy. Include clinical leadership where patient care or clinical documentation is affected.

Define the service being renewed: approved uses, sites, users, integrations and the relevant product or model versions. Separate current functionality from promised features. Do not treat a roadmap as evidence that the present service delivers value.

Use the original healthcare AI procurement evidence register as a starting point, then replace outdated assumptions with evidence from the completed contract period. Include exceptions and workflows where the tool was abandoned, not only successful uses.

The voluntary NIST AI Risk Management Framework recommends regular monitoring of third-party AI risks and benefits. It also considers resources, non-AI alternatives and mechanisms to disengage systems that perform inconsistently with their intended use. Renewal is a useful decision point for applying those principles.

Build a scorecard that does not hide unresolved risks

For each domain below, record an evidence link, its scope and age, the responsible reviewer and a proposed disposition. Use four plain-language ratings: supported, conditional, unacceptable and unknown.

“Supported” means relevant evidence meets the organisation's agreed criteria. “Conditional” means a specific, manageable gap has an owner and an enforceable remedy. “Unacceptable” means a concern exceeds the organisation's tolerance. “Unknown” means evidence is missing or cannot support a judgement.

Do not average these into a reassuring total. A favourable commercial assessment should not cancel an unacceptable safety or privacy finding. Agree decision gates before negotiations, proportionate to the use case. Missing material evidence should trigger investigation or restriction, not an assumption that nothing is wrong.

Value and price: compare the whole operating commitment

Ask what the organisation actually used and what changed in the workflow. Review locally relevant outcomes against a credible baseline, noting differences in staffing, demand or process that could explain apparent improvements. Distinguish adoption, satisfaction and task completion from demonstrated operational benefit.

Compare the next term's licence and usage charges with support, integration, training, review and correction costs. Identify unused seats, minimum volumes, premium features and potential exit charges. Finance should distinguish measured costs from estimates and unresolved assumptions.

Where evidence is insufficient, say so. Do not turn vendor benchmarks or staff enthusiasm into a return-on-investment claim. Consider narrower deployment, renegotiated terms or a viable non-AI workflow rather than framing full renewal as the only option.

Human review: test whether the workload is sustainable

Examine the work needed to make outputs usable: checking, correcting, escalating, documenting exceptions and training new staff. For clinical outputs, ask who remains accountable for review and whether the required expertise is available during routine work and periods of higher demand.

Request a representative sample of review records and feedback across sites and user groups. Include difficult cases, overrides and outputs discarded entirely. Look for work shifted to another team or performed outside scheduled hours.

A conditional rating needs a funded staffing or workflow remedy, not simply “continue human oversight”. Record who will do the work, how capacity will be checked and what happens if timely review becomes unavailable.

Changes: assess the service you would renew

Summarise material changes during the contract period, including functionality, models, integrations, approved uses and supplier dependencies. Cross-reference local testing and monitoring so reviewers can see whether evidence still applies to the current configuration.

This is not another change-control procedure. Its renewal purpose is to establish whether accumulated changes have altered the service's risk, value or support requirements enough to change the buying decision.

For generative AI, NIST's Generative AI Profile suggests continuous monitoring of deployed third-party systems and contract review covering changes, incident responsibilities and support. These are voluntary recommendations, not assurances that a vendor provides those capabilities.

Incidents and support: require evidence of resolution

Review incidents, near misses, repeated defects, service interruptions and complaints alongside support records. Distinguish “ticket closed” from a demonstrated remedy. Ask whether affected workflows were restored, corrective actions were tested and similar problems recurred.

Do not read an empty incident log as proof of safety. Check whether users know how to report concerns and whether reports from local teams reached the central record. Assess the quality and timeliness of vendor cooperation, not just contractual response targets.

The Generative AI Profile recommends after-action reviews to identify gaps in incident response and disclosure. Use that principle to ask which unresolved findings should prevent another full term, and which can be managed through specific contractual conditions.

Data use: reconcile current terms with actual practice

Compare the proposed renewal agreement, privacy terms, security documentation and relevant data-processing arrangements. Identify permissions for secondary use, model training, retention, recordings, derived data and access by subcontractors. Ask privacy and legal reviewers to resolve inconsistencies rather than relying on sales assurances.

For US HIPAA-covered arrangements where the supplier is a business associate, HHS explains that business associate contracts must establish permitted and required uses of protected health information and address safeguards, reporting and subcontractor restrictions. A signed agreement alone does not establish blanket compliance or authorise every proposed AI data use.

Revisit the questions in Eunoia's data-use and exit-terms review, but assess what actually occurred during the term and what the renewal would permit. Record unresolved permissions as decision issues.

Exit readiness: verify a usable route out

List what must remain available if the service ends: required records, relevant outputs, audit history and configuration information needed for continuity. Establish contractual export rights, formats, assistance, costs and timing. Do not assume access to a foundation model or portability of every AI artefact.

Propose a proportionate export rehearsal using authorised data and a receiving environment. Verify completeness and usability with the people who will depend on the records. Check a manual or alternative workflow, including staffing and access removal.

HHS guidance addresses return or destruction of business-associate-held protected health information at termination where feasible. Its FAQ on blocking access to PHI identifies blocking a covered entity's access to resolve a payment dispute as impermissible. Those protections do not replace a practical transition plan or guarantee portability of unrelated AI assets.

A proposed renewal approval checklist

Before the notice deadline, ask the decision owner to confirm:

  • The next term's scope, price, commitments and notice provisions are documented.
  • Local value evidence and total operating costs are reviewed, with uncertainties visible.
  • Human review has an accountable owner and a sustainable capacity plan.
  • Material changes are linked to evidence relevant to the current service.
  • Incidents and support failures have verified remedies or explicit restrictions.
  • Data-use permissions and applicable agreements have privacy and legal review.
  • Export, record continuity and fallback arrangements have been checked proportionately.
  • The decision, conditions, deadlines and authority to stop use are recorded.
  • Possible outcomes are full renewal, conditional renewal, reduced scope or planned exit. A short extension may be considered only where lawful, contractually available and acceptable for safety and continuity. It should have a defined end point, not become a way to postpone missing evidence indefinitely.

    Illustrative decision: useful service, incomplete renewal case

    Consider a hypothetical organisation using an AI documentation service. Staff describe it as helpful, and the vendor offers a discounted annual renewal. The evidence pack nevertheless shows inconsistent recording of correction work, unresolved questions about revised secondary-use terms and an export process that has not been rehearsed.

    Under this proposed framework, the value domain remains conditional rather than proven. Data use and exit readiness remain unknown. The discount does not turn those findings into supported ratings.

    The decision owner asks for legal clarification of the terms, a representative review-workload assessment and a usable export demonstration before approving a full annual commitment. If the gaps can be resolved within the notice period, the team reassesses. If not, it considers only an acceptable, bounded arrangement that preserves continuity, or prepares an orderly exit.

    This is an illustrative decision, not a client result. It demonstrates how renewal conditions should address the missing evidence rather than merely seek a better price.

    Frequently asked questions

    Is an annual AI vendor renewal scorecard legally required?

    This scorecard is a proposed operating framework, not a prescribed legal form. NIST guidance is voluntary. Applicable legal and contractual obligations still require separate review, including HIPAA business associate requirements where relevant. Completing the scorecard does not establish compliance.

    Can a discount justify renewing with unresolved risks?

    A discount can change the commercial assessment, but it should not override unacceptable risks or missing material evidence. Decide whether concerns can be resolved before commitment, managed through enforceable conditions or require reduced scope or exit.

    What if changing vendors would disrupt care or operations?

    Assess continuity explicitly. Compare renewal with a feasible transition or non-AI fallback, including staffing and access to required records. Where an extension is permissible and acceptable, give it clear limits and owners. Dependency should prompt transition planning, not automatic renewal.

    For help structuring accountable renewal decisions, explore Eunoia's AI governance services or contact the team to discuss evidence review, decision ownership and exit readiness for your healthcare organisation.

    References

  • NIST Artificial Intelligence Risk Management Framework, AI RMF 1.0
  • NIST AI 600-1: Generative Artificial Intelligence Profile
  • HHS Business Associate Contracts
  • HHS FAQ: Business associate blocking or terminating access to PHI
This article was produced by the Eunoia Consulting Co. Editorial Team. Eunoia Consulting Co. specialises in AI governance, healthcare operations, and data strategy for healthcare and veterinary organisations.